Erythropoietin therapy and cancer related anaemia: updated Swedish recommendations
2007 (English)In: Medical Oncology, ISSN 1357-0560, E-ISSN 1559-131X, Vol. 24, no 3, 267-272 p.Article in journal (Refereed) Published
Due to concerns related to treatment with erythropoietin (EPO) and possible negative effects on tumour control, a workshop was organised by the Medical Products Agency of Sweden with the aim to revise national treatment guidelines if needed. In patients with solid tumours, conflicting results have been reported with respect to tumour control and survival. Until further notice it is therefore recommended that EPO should be used restrictively in the treatment of patients with cancer and that the anticipated improvement in quality of life should be evaluated against potential risks.
Place, publisher, year, edition, pages
Humana Press, 2007. Vol. 24, no 3, 267-272 p.
Erythropoietin Anemia Epoetin Cancer therapy Safety Erythropoietin receptor
Medical and Health Sciences
IdentifiersURN: urn:nbn:se:liu:diva-101358DOI: 10.1007/s12032-007-0037-5PubMedID: 17873301OAI: oai:DiVA.org:liu-101358DiVA: diva2:666084